デフォルト表紙
市場調査レポート
商品コード
1239516

ジストニア治療薬市場:薬物タイプ別、投与経路別、流通チャネル別:世界の機会分析と産業予測、2021-2031年

Dystonia Drugs Market By Drug Type, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: | 発行: Allied Market Research | ページ情報: 英文 210 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.36円
ジストニア治療薬市場:薬物タイプ別、投与経路別、流通チャネル別:世界の機会分析と産業予測、2021-2031年
出版日: 2023年01月01日
発行: Allied Market Research
ページ情報: 英文 210 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ジストニア治療薬の世界市場は、2021年に8億667万米ドルと評価され、2022年から2031年にかけて5.5%のCAGRで成長し、2031年には13億7,867万米ドルに達すると予測されます。

ジストニアは、反復運動や捻り運動を引き起こす筋肉の不随意収縮を特徴とする運動障害と定義されることがあります。この疾患は、身体の一部(局所性ジストニア)または二部(分節性ジストニア)に影響を与えることもあれば、全身に影響を与えることもあり、一般的なジストニアと呼ばれます。これらの筋収縮は、軽度なものから重度のものまであり、異常な姿勢のために人の動作に影響を与えることもあります。また、男性よりも女性の方がこの症状になりやすいと言われています。ジストニアの症状としては、足がつる、首が不随意に引っ張られる、まばたきが止まらない、言葉が出ない、などがあります。また、常に筋肉が収縮するため、痛みや不快感にも悩まされます。しかし、ジストニアは特定の原因があるわけではなく、大脳基底核に関連する問題の結果、人の筋肉の収縮につながることで起こることが知られています。

ジストニアの治療には、ボツリヌス毒素(ボトックス)注射、数種類の薬物療法、手術などの方法があります。これらのアプローチは、ジストニアの治療のために個別に、または組み合わせて使用することができます。また、ジストニアの治療に用いられる薬剤には、筋弛緩剤、抗コリン剤、抗けいれん剤、ドーパミン作動性薬剤などがあります。これらの薬物に対する反応は個人差があり、また症状の重さによっても異なる場合があります。

ジストニア治療薬市場の成長を促す主な要因としては、先進国および新興国市場におけるジストニアの発生率の増加、パーキンソン病、ハンチントン病などの疾患の有病率の増加などが挙げられます。例えば、パーキンソン財団によると、米国では毎年9万人近くがパーキンソン病と診断され、世界中で1000万人以上の人々がパーキンソン病と共存しています。パーキンソン病とジストニアは互いに密接な関係にあり、パーキンソン病の有病率の増加はジストニアの発生率を増加させます。このため、ジストニア治療薬の需要がさらに高まり、ジストニア治療薬市場の成長が促進されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な影響要因
    • 主な投資機会
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入業者の脅威
    • 適度な競争の激しさ
  • 市場力学
    • 促進要因
      • 医薬品分野の研究開発活動の増加
      • ジストニアの発生率の増加
      • 神経疾患の有病率の増加
    • 抑制要因
      • 発展途上国におけるジストニアについての認識の欠如
    • 機会
      • 新興市場における成長機会
  • 市場におけるCOVID-19影響分析

第4章 ジストニア治療薬市場:薬物の種類別

  • 概要
    • 市場規模と予測
  • ドーパミン作動薬
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測:地域別
    • 市場シェア分析: 国別
  • GABA作動薬
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測:地域別
    • 市場シェア分析: 国別
  • 抗けいれん薬
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測:地域別
    • 市場シェア分析: 国別
  • その他
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測:地域別
    • 市場シェア分析: 国別

第5章 ジストニア治療薬市場:投与経路別

  • 概要
    • 市場規模と予測
  • オーラル
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測:地域別
    • 市場シェア分析: 国別
  • 注射可能
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測:地域別
    • 市場シェア分析: 国別

第6章 ジストニア治療薬市場:流通チャネル別

  • 概要
    • 市場規模と予測
  • 病院薬局
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測:地域別
    • 市場シェア分析: 国別
  • オンラインプロバイダー
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測:地域別
    • 市場シェア分析: 国別
  • ドラッグストアおよび小売薬局
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測:地域別
    • 市場シェア分析: 国別

第7章 ジストニア治療薬市場:地域別

  • 概要
    • 市場規模と予測:地域別
  • 北米
    • 主な動向と機会
    • 市場規模と予測:薬剤別
    • 市場規模と予測:投与経路別
    • 市場規模と予測:流通チャネル別
    • 市場規模と予測:国別
      • 米国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:薬剤別
      • 市場規模と予測:投与経路別
      • 市場規模と予測:流通チャネル別
      • カナダ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:薬剤別
      • 市場規模と予測:投与経路別
      • 市場規模と予測:流通チャネル別
      • メキシコ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:薬剤別
      • 市場規模と予測:投与経路別
      • 市場規模と予測:流通チャネル別
  • 欧州
    • 主な動向と機会
    • 市場規模と予測:薬剤別
    • 市場規模と予測:投与経路別
    • 市場規模と予測:流通チャネル別
    • 市場規模と予測:国別
      • ドイツ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:薬剤別
      • 市場規模と予測:投与経路別
      • 市場規模と予測:流通チャネル別
      • フランス
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:薬剤別
      • 市場規模と予測:投与経路別
      • 市場規模と予測:流通チャネル別
      • 英国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:薬剤別
      • 市場規模と予測:投与経路別
      • 市場規模と予測:流通チャネル別
      • イタリア
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:薬剤別
      • 市場規模と予測:投与経路別
      • 市場規模と予測:流通チャネル別
      • スペイン
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:薬剤別
      • 市場規模と予測:投与経路別
      • 市場規模と予測:流通チャネル別
      • その他欧州
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:薬剤別
      • 市場規模と予測:投与経路別
      • 市場規模と予測:流通チャネル別
  • アジア太平洋
    • 主な動向と機会
    • 市場規模と予測:薬剤別
    • 市場規模と予測:投与経路別
    • 市場規模と予測:流通チャネル別
    • 市場規模と予測:国別
      • 日本
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:薬剤別
      • 市場規模と予測:投与経路別
      • 市場規模と予測:流通チャネル別
      • 中国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:薬剤別
      • 市場規模と予測:投与経路別
      • 市場規模と予測:流通チャネル別
      • オーストラリア
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:薬剤別
      • 市場規模と予測:投与経路別
      • 市場規模と予測:流通チャネル別
      • インド
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:薬剤別
      • 市場規模と予測:投与経路別
      • 市場規模と予測:流通チャネル別
      • 韓国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:薬剤別
      • 市場規模と予測:投与経路別
      • 市場規模と予測:流通チャネル別
      • その他アジア太平洋地域
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:薬剤別
      • 市場規模と予測:投与経路別
      • 市場規模と予測:流通チャネル別
  • ラテンアメリカ・中東・アフリカ
    • 主な動向と機会
    • 市場規模と予測:薬剤別
    • 市場規模と予測:投与経路別
    • 市場規模と予測:流通チャネル別
    • 市場規模と予測:国別
      • ブラジル
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:薬剤別
      • 市場規模と予測:投与経路別
      • 市場規模と予測:流通チャネル別
      • サウジアラビア
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:薬剤別
      • 市場規模と予測:投与経路別
      • 市場規模と予測:流通チャネル別
      • 南アフリカ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:薬剤別
      • 市場規模と予測:投与経路別
      • 市場規模と予測:流通チャネル別
      • ラテンアメリカ・中東・アフリカの残り
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:薬剤別
      • 市場規模と予測:投与経路別
      • 市場規模と予測:流通チャネル別

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • トップ企業のポジショニング、2021年

第9章 企業プロファイル

  • Abbvie Inc
  • F. Hoffmann-La Roche Ltd.
  • Hameln Pharma Gmbh
  • Ipsen Pharma
  • Merz Pharmaceuticals, LLC
  • Novartis AG
  • Pfizer Inc.
  • Wellona Pharma
  • Teva Pharmaceutical Industries Limited
  • Amneal Pharmaceuticals LLC
図表

LIST OF TABLES

  • TABLE 01. GLOBAL DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. DYSTONIA DRUGS MARKET FOR DOPAMINERGIC AGENTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. DYSTONIA DRUGS MARKET FOR GABAERGIC AGENTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. DYSTONIA DRUGS MARKET FOR ANTICONVULSANTS DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. DYSTONIA DRUGS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. GLOBAL DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. DYSTONIA DRUGS MARKET FOR ORAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. DYSTONIA DRUGS MARKET FOR INJECTABLE, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. GLOBAL DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. DYSTONIA DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. DYSTONIA DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. DYSTONIA DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. DYSTONIA DRUGS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. NORTH AMERICA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. NORTH AMERICA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. NORTH AMERICA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. NORTH AMERICA DYSTONIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. U.S. DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. U.S. DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. U.S. DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. CANADA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. CANADA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. CANADA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. MEXICO DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. MEXICO DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. MEXICO DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. EUROPE DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. EUROPE DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. EUROPE DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. EUROPE DYSTONIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. GERMANY DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. GERMANY DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. GERMANY DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. FRANCE DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. FRANCE DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. FRANCE DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. UK DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. UK DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. UK DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. ITALY DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. ITALY DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. ITALY DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. SPAIN DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. SPAIN DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. SPAIN DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. REST OF EUROPE DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. REST OF EUROPE DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. REST OF EUROPE DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. JAPAN DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. JAPAN DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. JAPAN DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. CHINA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. CHINA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. CHINA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. AUSTRALIA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. AUSTRALIA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. AUSTRALIA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. INDIA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. INDIA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. INDIA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. SOUTH KOREA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. SOUTH KOREA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. SOUTH KOREA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. LAMEA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. LAMEA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. LAMEA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. LAMEA DYSTONIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. BRAZIL DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. BRAZIL DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. BRAZIL DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. SAUDI ARABIA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. SAUDI ARABIA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. SAUDI ARABIA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. SOUTH AFRICA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. SOUTH AFRICA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. SOUTH AFRICA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. REST OF LAMEA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. REST OF LAMEA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. REST OF LAMEA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. ABBVIE INC: KEY EXECUTIVES
  • TABLE 88. ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 89. ABBVIE INC: PRODUCT SEGMENTS
  • TABLE 90. ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 91. ABBVIE INC: KEY STRATERGIES
  • TABLE 92. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 93. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 94. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 95. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 96. HAMELN PHARMA GMBH: KEY EXECUTIVES
  • TABLE 97. HAMELN PHARMA GMBH: COMPANY SNAPSHOT
  • TABLE 98. HAMELN PHARMA GMBH: PRODUCT SEGMENTS
  • TABLE 99. HAMELN PHARMA GMBH: PRODUCT PORTFOLIO
  • TABLE 100. IPSEN PHARMA: KEY EXECUTIVES
  • TABLE 101. IPSEN PHARMA: COMPANY SNAPSHOT
  • TABLE 102. IPSEN PHARMA: PRODUCT SEGMENTS
  • TABLE 103. IPSEN PHARMA: PRODUCT PORTFOLIO
  • TABLE 104. MERZ PHARMACEUTICALS, LLC: KEY EXECUTIVES
  • TABLE 105. MERZ PHARMACEUTICALS, LLC: COMPANY SNAPSHOT
  • TABLE 106. MERZ PHARMACEUTICALS, LLC: PRODUCT SEGMENTS
  • TABLE 107. MERZ PHARMACEUTICALS, LLC: PRODUCT PORTFOLIO
  • TABLE 108. MERZ PHARMACEUTICALS, LLC: KEY STRATERGIES
  • TABLE 109. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 110. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 111. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 112. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 113. PFIZER INC.: KEY EXECUTIVES
  • TABLE 114. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 115. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 116. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 117. WELLONA PHARMA: KEY EXECUTIVES
  • TABLE 118. WELLONA PHARMA: COMPANY SNAPSHOT
  • TABLE 119. WELLONA PHARMA: PRODUCT SEGMENTS
  • TABLE 120. WELLONA PHARMA: PRODUCT PORTFOLIO
  • TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 122. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 123. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 124. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 125. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 126. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 127. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
  • TABLE 128. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 129. AMNEAL PHARMACEUTICALS LLC: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. DYSTONIA DRUGS MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF DYSTONIA DRUGS MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN DYSTONIA DRUGS MARKET (2022-2031)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALDYSTONIA DRUGS MARKET
  • FIGURE 10. DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR DOPAMINERGIC AGENTS, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR GABAERGIC AGENTS, BY COUNTRY 2021-2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR ANTICONVULSANTS DRUGS, BY COUNTRY 2021-2031(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 15. DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR ORAL, BY COUNTRY 2021-2031(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR INJECTABLE, BY COUNTRY 2021-2031(%)
  • FIGURE 18. DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 22. DYSTONIA DRUGS MARKET BY REGION, 2021
  • FIGURE 23. U.S. DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. CANADA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. MEXICO DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. GERMANY DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. FRANCE DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. UK DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. ITALY DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. SPAIN DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. REST OF EUROPE DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. JAPAN DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. CHINA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. AUSTRALIA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. INDIA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. SOUTH KOREA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. BRAZIL DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. SAUDI ARABIA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SOUTH AFRICA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. REST OF LAMEA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: DYSTONIA DRUGS MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2021
  • FIGURE 49. ABBVIE INC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 50. ABBVIE INC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 51. ABBVIE INC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 52. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 53. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 54. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 55. IPSEN PHARMA: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 56. IPSEN PHARMA: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 57. IPSEN PHARMA: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 58. NOVARTIS AG: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 59. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 60. NOVARTIS AG: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 61. PFIZER INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 62. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 63. PFIZER INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 64. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 65. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 66. AMNEAL PHARMACEUTICALS LLC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 67. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE BY SEGMENT, 2021 (%)
目次
Product Code: A13938

The global dystonia drugs market was valued at $806.67 million in 2021, and is projected to reach $1,378.67 million by 2031, registering a CAGR of 5.5% from 2022 to 2031. Dystonia may be defined as a movement disorder which is characterized by involuntary contraction of the muscles which causes repetitive or twisting movements. This condition may affect a single (focal dystonia) or two parts (segmental dystonia) of the body or can affect the whole body of the patient which is termed as (general dystonia). These muscle contractions can be mild or severe in nature and can affect the movement of the person due to abnormal posture. Moreover, women are more prone to the condition than the men. Symptoms of dystonia include the cramping of the foot, involuntary pulling of the neck, uncontrollable blinking, speech difficulties and others. People also suffer from pain and discomfort as a result of constant muscle contractions. However, dystonia does not have a specific cause but is known to occur as a result of problems related to basal ganglia which leads to muscle contractions in the person.  

Major approaches for treating dystonia include botulinum toxin (botox) injections, several drug types of medication and surgery. These approaches can be used individually or in combination for treating dystonia. In addition, the drugs used for the treatment of dystonia includes muscle relaxants, anticholinergic drugs, anticonvulsants, dopaminergic agents and others. The response to these medications depends on different individuals and may also differ according to the severity of the condition.  

The major factor driving the growth of dystonia drugs market includes the increase in incidences of dystonia in developed and developing regions, along with increase in prevalence of conditions such as Parkinson's disease, Huntington's disease and others. For instance, according to The Parkinson's Foundation, nearly 90,000 people in the U.S. are diagnosed with Parkinson's disease each year and more than 10 million people worldwide are living with Parkinson's disease. As Parkison's disease and dystonia are closely related to each other, increase in prevalence of Parkinsons diseases increases the incidence of dystonia. This further increases the demand for dystonia treatment drugs and thus, propels the growth of dystonia drugs market.  

In addition, major key players are offering a wide range of dystonia drug products with significant product differentiation. Manufacturers are focusing on developing novel formulations which are highly potent and effective and are easily accessible to the patients. Thus, increase in such product offering by the key market players is anticipated to increase the prescription of various dystonia medications by healthcare providers and patients and thereby augment the growth of the market.  

Furthermore, the increase in funding and investment by the key market players in the developing regions is boosting the market growth. Regions such as Asia-Pacific have been the point of attraction for the investors owing to the presence of essential resources in this region. Moreover, Asia-Pacific is emerging as a pharmaceutical hub for supply of medications and devices around the globe. This also propels the growth dystonia drugs market. 

Although various key factors are driving the growth of the market, there are few factors such as lack of awareness about the condition and its treatment options in underdeveloped countries is providing hindrance to the growth of the market. Dystonia is often left undiagnosed as people have less knowledge regarding the condition. Also, people in developing countries are unaware about the advanced treatment options available for dystonia. Also, availability of new alternate treatment options such as surgeries and other physical therapies, further acts as a restraint to the growth of the market.  

The global dystonia drugs market is segmented on the basis of drug type, distribution channel and region. By drug type, the market is categorized into dopaminergic agents, GABAergic agents, anticonvulsants, and others. On the basis of route of administration, the market is segmented into oral and injection. Based on distribution channel, the market is categorized into hospital pharmacies, online providers and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

Major Key players that operate in the global Dystonia Drugs Market are: AbbVie Inc., Amneal Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd, Hameln Pharma GmbH, Ipsen Pharma, Merz Pharmaceuticals, LLC, Novartis AG, Pfizer Inc., Teva Pharmaceuticals and Wellona Pharma.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the dystonia drugs market analysis from 2021 to 2031 to identify the prevailing dystonia drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the dystonia drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global dystonia drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

  • Anticonvulsants drugs
  • Others
  • Dopaminergic agents
  • GABAergic agents

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Hospital Pharmacies
  • Online Providers
  • Drug Stores and Retail Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players

  • Hameln Pharma Gmbh
  • Ipsen Pharma
  • Novartis AG
  • Pfizer Inc.
  • Wellona Pharma
  • Teva Pharmaceutical Industries Limited
  • Amneal Pharmaceuticals LLC
  • F. Hoffmann-La Roche Ltd.
  • Merz Pharmaceuticals, LLC
  • Abbvie Inc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate bargaining power of buyers
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate threat of new entrants
    • 3.3.5. Moderate intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in R&D activities in pharmaceutical field
      • 3.4.1.2. Increase in incidences of dystonia
      • 3.4.1.3. Increase in prevalence of neurological disorders
    • 3.4.2. Restraints
      • 3.4.2.1. Lack of awareness about dystonia in underdeveloped nations
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunity in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: DYSTONIA DRUGS MARKET, BY DRUG TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Dopaminergic agents
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. GABAergic agents
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Anticonvulsants drugs
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oral
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Injectable
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Online Providers
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Drug Stores and Retail Pharmacies
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: DYSTONIA DRUGS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drug Type
    • 7.2.3. Market size and forecast, by Route of Administration
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drug Type
      • 7.2.5.1.3. Market size and forecast, by Route of Administration
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drug Type
      • 7.2.5.2.3. Market size and forecast, by Route of Administration
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drug Type
      • 7.2.5.3.3. Market size and forecast, by Route of Administration
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drug Type
    • 7.3.3. Market size and forecast, by Route of Administration
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drug Type
      • 7.3.5.1.3. Market size and forecast, by Route of Administration
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drug Type
      • 7.3.5.2.3. Market size and forecast, by Route of Administration
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drug Type
      • 7.3.5.3.3. Market size and forecast, by Route of Administration
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drug Type
      • 7.3.5.4.3. Market size and forecast, by Route of Administration
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drug Type
      • 7.3.5.5.3. Market size and forecast, by Route of Administration
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drug Type
      • 7.3.5.6.3. Market size and forecast, by Route of Administration
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drug Type
    • 7.4.3. Market size and forecast, by Route of Administration
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drug Type
      • 7.4.5.1.3. Market size and forecast, by Route of Administration
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drug Type
      • 7.4.5.2.3. Market size and forecast, by Route of Administration
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drug Type
      • 7.4.5.3.3. Market size and forecast, by Route of Administration
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. India
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drug Type
      • 7.4.5.4.3. Market size and forecast, by Route of Administration
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Drug Type
      • 7.4.5.5.3. Market size and forecast, by Route of Administration
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Drug Type
      • 7.4.5.6.3. Market size and forecast, by Route of Administration
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drug Type
    • 7.5.3. Market size and forecast, by Route of Administration
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drug Type
      • 7.5.5.1.3. Market size and forecast, by Route of Administration
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drug Type
      • 7.5.5.2.3. Market size and forecast, by Route of Administration
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Drug Type
      • 7.5.5.3.3. Market size and forecast, by Route of Administration
      • 7.5.5.3.4. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Drug Type
      • 7.5.5.4.3. Market size and forecast, by Route of Administration
      • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Abbvie Inc
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. F. Hoffmann-La Roche Ltd.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Hameln Pharma Gmbh
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
  • 9.4. Ipsen Pharma
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Merz Pharmaceuticals, LLC
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Key strategic moves and developments
  • 9.6. Novartis AG
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Pfizer Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Wellona Pharma
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
  • 9.9. Teva Pharmaceutical Industries Limited
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Amneal Pharmaceuticals LLC
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments